for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover Journal of Clinical and Experimental Hepatology
   [3 followers]  Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 0973-6883
     Published by Elsevier Homepage  [2575 journals]
  • Immortalization of Human Fetal Hepatocyte by Ectopic Expression of Human
           Telomerase Reverse Transcriptase, Human Papilloma Virus (E7) and Simian
           Virus 40 Large T (SV40 T) Antigen Towards Bioartificial Liver Support
    • Authors: Shibashish Giri; Augustinus Bader
      Pages: 191 - 201
      Abstract: Generation of genetically stable and non-tumoric immortalization cell line from primary cells would be enormously useful for research and therapeutic purposes, but progress towards this goal has so far been limited. It is now universal acceptance that immortalization of human fetal hepatocytes based on recent advances of telomerase biology and oncogene, lead to unlimited population doubling could be the possible source for bioartificial liver device.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-09-18
      DOI: 10.1016/j.jceh.2014.08.001
      Issue No: Vol. 4, No. 3 (2014)
  • Association of TNF-α Promoter Polymorphism with HBV Associated
           Disease Outcome Among HBV Infected Patients from Orissa, Southern Part of
           East India
    • Authors: Rajesh Panigrahi; Neelakshi Sarkar, Avik Biswas, Ananya Pal, Debraj Saha, Shivaram P. Singh, Manas K. Panigrahi, Manikanana Bandopadhyay, Sekhar Chakrabarti, Runu Chakravarty
      Pages: 202 - 208
      Abstract: TNF-α promoter polymorphism has been known to be a potential predictive factor in patients with HBV infection. We therefore tried to investigate whether the TNF-α promoter polymorphism at position −238, −857 and −863 was associated with the outcome of HBV infection in a population from Orissa, southern part of East India.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-09-18
      DOI: 10.1016/j.jceh.2014.08.002
      Issue No: Vol. 4, No. 3 (2014)
  • Hepatitis B Immunoglobulin Prophylaxis after Liver Transplantation:
           Experience in a Tertiary Transplant Centre
    • Authors: Joy Varghese; Deepti Sachan, Mettu S. Reddy, Tom Cherian, Dinesh Jothimani, Kota Venugopal, Olithselvan Arikichenin, Rajasekar Perumalla, Gomathy Narasimhan, Vivekananthan Shanmugam, Srinivasan Vijaya, Jayanthi Venkataraman, Mohamed Rela
      Pages: 209 - 213
      Abstract: Prophylaxis with hepatitis B immunoglobulin (HBIG) and nucleoside analogs can prevent hepatitis B virus (HBV) recurrence after liver transplant (LT).
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-08-12
      DOI: 10.1016/j.jceh.2014.07.007
      Issue No: Vol. 4, No. 3 (2014)
  • Hepatitis C Virus Treatment in the ‘Real-World’: How Well Do
           ‘Real’ Patients Respond'
    • Authors: N. Deborah Friedman; Joanne H. Green, Hanna M. Weber, Shiny Stephen, Stephen E. Lane, Alvin Y. Ting, Jonathan P. Watson
      Pages: 214 - 220
      Abstract: Published clinical trials of the treatment of HCV are largely multicentre prospective pharmaceutical trials. Patients in clinical trials tend to have more favorable outcomes than patients in the ‘real-world’, due to strict patient selection and differences in treatment conditions and available resources.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-07-25
      DOI: 10.1016/j.jceh.2014.07.003
      Issue No: Vol. 4, No. 3 (2014)
  • Role of Mycophenolate Mofetil for the Treatment of Autoimmune
           Hepatitis—An Observational Study
    • Authors: Dinesh Jothimani; Mathew E. Cramp, Tim J.S. Cross
      Pages: 221 - 225
      Abstract: Eighty percent (80%) of patients with Autoimmune hepatitis (AIH) respond to a combination of prednisolone and Azathioprine (AZA). Choice of treatment is limited for those who do not respond to this standard therapy. We evaluated the role of Mycophenolate mofetil (MMF) as a second line therapy in AIH.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-06-24
      DOI: 10.1016/j.jceh.2014.05.003
      Issue No: Vol. 4, No. 3 (2014)
  • Accuracy of Rapid Point-of-Care Diagnostic Tests for Hepatitis B Surface
           Antigen—A Systematic Review and Meta-analysis
    • Authors: Mehnaaz S. Khuroo; Naira S. Khuroo, Mohammad S. Khuroo
      Pages: 226 - 240
      Abstract: Rapid point-of-care tests provide plausible diagnostic strategy for hepatitis B surface antigen (HBsAg) in low resource areas. However, their utility depends upon their overall performance. Our objective was to meta-analyze the diagnostic accuracy of rapid point-of-care tests for HBsAg.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-08-28
      DOI: 10.1016/j.jceh.2014.07.008
      Issue No: Vol. 4, No. 3 (2014)
  • Designing Immune Therapy for Chronic Hepatitis B
    • Authors: Sheikh Mohammad Fazle Akbar; Mamun Al-Mahtab, Yoichi Hiasa
      Pages: 241 - 246
      Abstract: Presently-available antiviral drugs may not be a satisfactory option for treatment of patients with chronic hepatitis B (CHB). In spite of presence of several antiviral drugs, sustained off-treatment clinical responses are not common in CHB patients treated with antiviral drugs. In addition, antiviral drug treatment may have limited effects on blocking the progression of HBV-related complications. However, substantial long-term risk of viral resistance and drug toxicity are related with maintenance antiviral therapy in CHB patients with presently-available antiviral agents.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-06-26
      DOI: 10.1016/j.jceh.2014.06.008
      Issue No: Vol. 4, No. 3 (2014)
  • Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension
           (NCIPH)—Newer Insights into Pathogenesis and Emerging Newer
           Treatment Options
    • Authors: Ashish Goel; Joshua E. Elias, Chundamannil E. Eapen, Banumathi Ramakrishna, Elwyn Elias
      Pages: 247 - 256
      Abstract: Chronic microangiopathy of portal venules results in idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH). Recent data suggest a role for vasoactive factors of portal venous origin in the pathogenesis of this ‘pure’ vasculopathy of the liver. Enteropathies (often silent), are an important ‘driver’ of this disease. NCIPH is under-recognized and often mis-labeled as cryptogenic cirrhosis. Liver biopsy is needed to prove the diagnosis of NCIPH. In these patients, with advancing disease and increased porto-systemic shunting, the portal venous vasoactive factors bypass the liver filter and contribute to the development of pulmonary vascular endothelial disorders—porto-pulmonary hypertension and hepato-pulmonary syndrome as well as mesangiocapillary glomerulonephritis.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-07-28
      DOI: 10.1016/j.jceh.2014.07.005
      Issue No: Vol. 4, No. 3 (2014)
  • Mesenteric Venous Thrombosis
    • Authors: Bashar Hmoud; Ashwani K. Singal, Patrick S. Kamath
      Pages: 257 - 263
      Abstract: Mesenteric vein thrombosis is increasingly recognized as a cause of mesenteric ischemia. Acute thrombosis commonly presents with abdominal pain and chronic type with features of portal hypertension. Contrast enhanced CT scan of abdomen is quite accurate for diagnosing and differentiating two types of mesenteric venous thrombosis. Prothrombotic state, hematological malignancy, and local abdominal inflammatory conditions are common predisposing conditions. Over the last decade, JAK-2 (janus kinase 2) mutation has emerged as an accurate biomarker for diagnosis of myeloproliferative neoplasm, an important cause for mesenteric venous thrombosis.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-04-14
      DOI: 10.1016/j.jceh.2014.03.052
      Issue No: Vol. 4, No. 3 (2014)
  • Terbinafine Induced Liver Injury: A Case Report
    • Authors: Narendra S. Choudhary; Hardik Kotecha, Neeraj Saraf, Dheeraj Gautam, Sanjiv Saigal
      Pages: 264 - 265
      Abstract: Drug induced liver injury (DILI) is a cause of significant morbidity; timely diagnosis is important and requires a high index of suspicion. Terbinafine induced liver injury is rare. We report a case of Terbinafine induced hepatitis-cholestatic injury. The patient had a prolonged recovery phase lasting 3 months after discontinuation of drug.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-04-07
      DOI: 10.1016/j.jceh.2014.03.040
      Issue No: Vol. 4, No. 3 (2014)
  • Abnormality in Hepatobiliary Scintigraphy in a Liver Transplant Recepient
    • Authors: Shanmuga S. Palaniswamy; Padma Subramanyam
      First page: 266
      Abstract: Hepatobiliary scintigraphy (HBS) using 99mTc mebrofenin, is routinely performed to assess biliary tract complications. In the immediate post liver transplant period, bile leak, obstruction and vascular insufficiency are commonly encountered complications. We present 99mTc Mebrofenin HBS images of a 50 year old male patient with cirrhosis and portal hypertension who underwent live donor related liver transplant. Dynamic (Figure 1a) and static high resolution images of anterior abdomen (Figure 1b) acquired upto 2 h are presented.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-09-18
      DOI: 10.1016/j.jceh.2014.08.009
      Issue No: Vol. 4, No. 3 (2014)
  • Gut Microbiome and Liver Diseases
    • Authors: Shalimar
      Pages: 267 - 268
      Abstract: Nan Qin1,2, Fengling Yang1, Ang Li1, Edi Prifti3, Yanfei Chen1, Li Shao1,2, Jing Guo1, Emmanuelle Le Chatelier3, Jian Yao1,2, Lingjiao Wu1, Jiawei Zhou1, Shujun Ni1, Lin Liu1, Nicolas Pons3, Jean Michel Batto3, Sean P. Kennedy3, Pierre Leonard3, Chunhui Yuan1, Wenchao Ding1, Yuanting Chen1, Xinjun Hu1, Beiwen Zheng1,2, Guirong Qian1, Wei Xu1, S. Dusko Ehrlich3,4, Shusen Zheng2,5 and Lanjuan Li1,2 Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014 Jul 23 [Epub ahead of print].
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-09-18
      DOI: 10.1016/j.jceh.2014.08.010
      Issue No: Vol. 4, No. 3 (2014)
  • Hepatobiliary Quiz 11 (2014)
    • Authors: Swastik Agrawal; Radha K. Dhiman
      Pages: 269 - 270
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-09-14
      DOI: 10.1016/j.jceh.2014.08.006
      Issue No: Vol. 4, No. 3 (2014)
  • Hepatobiliary Quiz 11 (2014)
    • Authors: Swastik Agrawal; Radha K. Dhiman
      Pages: 271 - 275
      Abstract: The model for end stage liver disease (MELD) score at time of conception is predictive of outcomes of pregnancy patients with cirrhosis. Patients with a MELD score of ≤6 are unlikely to have significant complications while pregnancy should be avoided in patients with MELD score of ≥10.1 Pregnancy is rare in patients with cirrhosis due to amenorrhea and infertility with the incidence of cirrhosis in pregnancy has been reported as 1 in 5950 pregnancies.2 Also, continuation of pregnancy to term is less common with fetal wastage in 10%–66% cases and spontaneous first trimester abortion seen in about 20% cases.
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-09-14
      DOI: 10.1016/j.jceh.2014.08.005
      Issue No: Vol. 4, No. 3 (2014)
  • Bile Leak Leading to Lesser Sac Bile Collection Masquerading as Stomach in
           Hepatobiliary Scintigraphy
    • Authors: Shanmuga S. Palaniswamy; Padma Subramanyam
      Pages: 276 - 278
      Abstract: Images show normal tracer distribution in graft hepatocytes. Abnormal bile collection seen along the inferior margin of the liver which progressively collects at lesser sac (LS) displacing and compressing stomach (S) superolaterally (confirmed in Magnetic Resonance Imaging [MRI] coronal section). There is normal progression of tracer into intestinal loops. The first minute of dynamic image shows a large cold defect at the anatomical site of stomach which is in fact the unlabeled bile collection at LS (thin arrow) (Figure 1).
      Citation: Journal of Clinical and Experimental Hepatology 4, 3 (2014)
      PubDate: 2014-09-18
      DOI: 10.1016/j.jceh.2014.09.001
      Issue No: Vol. 4, No. 3 (2014)
  • Minimal Hepatic Encephalopathy Impairs Quality of Life
    • Authors: Swastik Agrawal; Sridharan Umapathy, Radha K. Dhiman
      Abstract: Minimal hepatic encephalopathy (MHE) is the mildest form of the spectrum of neurocognitive impairment in cirrhosis. It is a frequent occurrence in patients of cirrhosis and is detectable only by specialized neurocognitive testing. MHE is a clinically significant disorder which impairs daily functioning, driving performance, work capability and learning ability. It also predisposes to the development of overt hepatic encephalopathy, increased falls and increased mortality. This results in impaired quality of life for the patient as well as significant social and economic burden for health providers and care givers.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-12-17
      DOI: 10.1016/j.jceh.2014.11.006
  • An Elderly Man with a Huge Liver
    • Authors: Vishal Sharma; Abhinav Aggarwal, Ritesh Singla, Naveen Kalra, Yogesh K. Chawla
      Abstract: A 71-year old male presented with generalised gradual onset abdominal distension for 15 days accompanied by abdominal discomfort without any history of loss of appetite or weight. He was a chronic tobacco chewer and a non-alcoholic. Systemic examination revealed a nodular firm liver and presence of ascites but no splenomegaly. Rest of his systemic examination was normal. His liver function tests were deranged with total bilirubin: 1.6 mg/dL (normal, 0.3–1.0 mg/dL), alanine transaminase: 74.8 (Normal, 2–45 IU/L), aspartate transaminase: 90.7 (Normal, 2–35 IU/L), serum alkaline phosphatase: 868 (Normal, 42–128 IU/L) and serum albumin 3.1 mg/dL (normal, 3.5–5 mg/dL).
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-12-12
      DOI: 10.1016/j.jceh.2014.12.001
  • Giant Hemangioma Causing Budd-Chiari Syndrome
    • Authors: Vishal Sharma; Abhinav Aggarwal, Ritesh Singla, Naveen Kalra, Yogesh K. Chawla
      Abstract: Triphasic CT scan of abdomen showed diffuse, large heterogeneous area involving left lobe and anterior segments of right lobe of liver with multiple similar character lesions in posterior segment with centripetal filling suggestive of liver hemangiomatosis (Figure 1A, B and C). The giant hemangioma was seen causing mass effect in form of compression of right hepatic vein and non-visualization of middle and left hepatic veins with chinking of intrahepatic inferior vena cava consistent with Budd-Chiari syndrome (Figure 1B).
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-12-12
      DOI: 10.1016/j.jceh.2014.12.002
  • Hepatobiliary Quiz–12 (2014)
    • Authors: Swastik Agrawal; Radha K. Dhiman
      Abstract: Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH) has been described by various terminologies such as idiopathic portal hypertension, non-cirrhotic portal fibrosis (NCPF), nodular regenerative hyperplasia (NRH), incomplete septal cirrhosis, partial nodular transformation of the liver, benign intrahepatic portal hypertension and hepatoportal sclerosis. Although, these diseases differ in some details in their description and defining criteria, they are believed to represent variations in appearance of a single pathological entity.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-12-11
      DOI: 10.1016/j.jceh.2014.11.004
  • Hepatobiliary Quiz–12 (2014)
    • Authors: Swastik Agrawal; Radha K. Dhiman
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-12-10
      DOI: 10.1016/j.jceh.2014.11.003
  • Potential Newer Therapeutic Targets for Hepatitis B Virus Drug Development
    • Authors: Shalimar
      Abstract: Christian Königera,b, Ida Wingerta, Moritz Marsmanna, Christine Röslera, Jürgen Becka,, and Michael Nassala. Involvement of the host DNA repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):E4244–53.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-12-06
      DOI: 10.1016/j.jceh.2014.11.001
  • Hydatid Cyst of Liver Presented as Obstructive Jaundice in Pregnancy;
           Managed by PAIR: Report of a Common Procedure in a Rare Setting from India
    • Authors: Jayant K. Ghosh; Sundeep K. Goyal, Manas K. Behera, Vinod K. Dixit, Ashok K. Jain
      Abstract: Incidence of Hydatid disease in pregnancy ranges from 1in 20,000 to 1 in 30,000. The most common site of hydatid cysts is the liver. The diagnosis of liver hydatid cysts is not difficult but the management during pregnancy is problematic. Both medical and surgical treatments are available but there is no consensus and each case has to be individualized. We present a case of liver hydatid cyst presented with obstructive jaundice during pregnancy which was managed by Puncture of the cyst under USG guidance; Aspiration of the cystic fluid, Injection of hypertonic saline, and Re-aspiration of solution without drainage (PAIR) and albendazole therapy.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-12-06
      DOI: 10.1016/j.jceh.2014.11.002
  • Definition and Nomenclature of Hepatic Encephalopathy
    • Authors: Narayan Dharel; Jasmohan S. Bajaj
      Abstract: Hepatic encephalopathy (HE) can manifest with a broad range of neuropsychiatric abnormalities of varying severity, acuity and time course with significant clinical implications. Lack of precise nomenclature and classification had hampered research in this complex clinical problem. A multiaxial classification system based on underlying etiology, clinical severity, time course and presence or absence of precipitating factors has been developed over the recent years and has been fully incorporated in the newly published AASLD-EASL guidelines on HE management.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-11-28
  • Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease)
    • Authors: Cathy Q. Fan; James M. Crawford
      Abstract: Hepatic sinusoidal obstruction syndrome (SOS) is an obliterative venulitis of the terminal hepatic venules, which in its more severe forms imparts a high risk of mortality. SOS, also known as veno-occlusive disease (VOD), occurs as a result of cytoreductive therapy prior to hematopoietic stem cell transplantation (HSCT), following oxaliplatin-containing adjuvant or neoadjuvant chemotherapy for colorectal carcinoma metastatic to the liver and treated by partial hepatectomy, in patients taking pyrrolizidine alkaloid-containing herbal remedies, and in other particular settings such as the autosomal recessive condition of veno-occlusive disease with immunodeficiency (VODI).
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-11-13
  • Acute-on-Chronic Liver Failure: Recent Concepts
    • Authors: Richard Moreau; Rajiv Jalan, Vicente Arroyo
      Abstract: A proportion of patients hospitalized for an acute complication of cirrhosis are at high risk of short-term death. The term Acute-on-Chronic Liver Failure (ACLF) is used to characterize these patients. Until recently there was no evidence-based definition of ACLF. In 2013 a definition has been proposed based on results of a large prospective observational European study, called “European Association for the Study of the Liver (EASL)–Chronic Liver Failure (CLIF) Consortium Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC)” study.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-10-03
      DOI: 10.1016/j.jceh.2014.09.003
  • Wild Mushroom Poisoning in North India: Case Series with Review of
    • Authors: Nipun Verma; Ashish Bhalla, Susheel Kumar, Radha K. Dhiman, Yogesh K. Chawla
      Abstract: Mushroom is an important constituent of diet in many ethnic tribes in India. Ethnic Indian tribes are known to consume nearly 283 species of wild mushrooms out of 2000 species recorded world over. Although they are experts in distinguishing the poisonous from edible mushrooms, yet occasional cases of toxicity are reported due to accidental consumption of poisonous mushrooms. We report amanita like toxicity in a family after consumption of wild mushrooms resulting in fatal outcome.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-09-25
      DOI: 10.1016/j.jceh.2014.09.004
  • Encephalopathy in Wilson Disease: Copper Toxicity or Liver Failure'
    • Authors: Peter Ferenci; Tomasz Litwin, Joanna Seniow, Anna Czlonkowska
      Abstract: Hepatic encephalopathy (HE) is a complex syndrome of neurological and psychiatric signs and symptoms that is caused by portosystemic venous shunting with or without liver disease irrespective of its etiology. The most common presentation of Wilson disease (WD) is liver disease and is frequently associated with a wide spectrum of neurological and psychiatric symptoms. The genetic defect in WD leads to copper accumulation in the liver and later in other organs including the brain. In a patient presenting with Wilsonian cirrhosis neuropsychiatric symptoms may be caused either by the metabolic consequences of liver failure or by copper toxicity.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-09-20
      DOI: 10.1016/j.jceh.2014.09.002
  • Acute Portal Vein Thrombosis, No Longer a Contraindication for
           Transjugular Intrahepatic Porto-Systemic Shunt (TIPS) Insertion
    • Authors: Suraj Mammen; Shyamkumar N. Keshava, Sajith Kattiparambil
      Abstract: Portal vein thrombosis, once considered as a contraindication to transjugular intrahepatic porto-systemic shunt (TIPS) is now considered as an indication. We report a case with clinical and technical success in a patient with Budd Chiari syndrome and acute portal venous thrombosis. Though it is a well-established option, with the best of our knowledge, we could not find a report from India.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-09-20
      DOI: 10.1016/j.jceh.2014.08.008
  • Role of Human Albumin in the Management of Complications of Liver
    • Authors: Mauro Bernardi; Carmen S. Ricci, Giacomo Zaccherini
      Abstract: Albumin is a negatively charged, relatively small protein synthesized by liver cells. Is the most abundant protein in extracellular fluid and accounts for about 70% of the plasma colloid osmotic pressure. Therefore it plays a crucial role in regulating fluid distribution in the body. In addition, albumin possesses functional domains with important non-oncotic properties, such as potent anti-oxydant and scavenging activities, binding of highly toxic reactive metal species and a great amount of endogenous and exogenous substances.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-09-20
      DOI: 10.1016/j.jceh.2014.08.007
  • Macrophages from Patients with Cirrhotic Ascites Showed Function
           Alteration of Host Defense Receptor
    • Authors: Abdel Motaal M. Ahmed; Abdel Gadir Y. Kadaru, Ibtihal Omer, Ahmed M. Musa, Khalid Enan, Isam M. El Khidir, Roger Williams
      Abstract: Patients with cirrhotic ascites (PCA) are susceptible to spontaneous bacterial peritonitis (SBP) which has increased morbidity and mortality. Since some host defense aspects of peritoneal macrophages (PMф) from PCA are altered this study examined factors related to receptor-mediated phagocytosis.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-09-17
      DOI: 10.1016/j.jceh.2014.08.003
  • Sustained Virological Response Rates to Antiviral Therapy in Genotype 1
           and 3 Chronic Hepatitis C Patients: A Study from North India
    • Authors: Varun Gupta; Ashish Kumar, Praveen Sharma, Pankaj Tyagi, Naresh Bansal, Vikas Singla, Anil Arora
      Abstract: In India, both genotype 3 and 1 are predominant genotypes in patients with chronic hepatitis C (CHC). However, there is scanty data on sustained viral response (SVR) rate with conventionally recommended dual therapy with PEG-IFN and ribavirin.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-09-15
      DOI: 10.1016/j.jceh.2014.08.004
  • Neuroinflammation in Hepatic Encephalopathy: Mechanistic Aspects
    • Authors: Arumugam R. Jayakumar; Kakulavarapu V. Rama Rao, Michael D. Norenberg
      Abstract: Hepatic encephalopathy (HE) is a major neurological complication of severe liver disease that presents in acute and chronic forms. While elevated brain ammonia level is known to be a major etiological factor in this disorder, recent studies have shown a significant role of neuroinflammation in the pathogenesis of both acute and chronic HE. This review summarizes the involvement of ammonia in the activation of microglia, as well as the means by which ammonia triggers inflammatory responses in these cells.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-08-05
      DOI: 10.1016/j.jceh.2014.07.006
  • Clinical Neurophysiology of Hepatic Encephalopathy
    • Authors: Piero Amodio; Sara Montagnese
      Abstract: Hepatic encephalopathy (HE) has relevant impact on the quality of life of patients and their caregivers and causes relevant costs because of hospitalizations and work days lost. Its quantification is important to perform adequate clinical trials on this relevant complication of cirrhosis and portal-systemic shunting. Clinical neurophysiology, which detects functional alterations of the nervous system, has been applied to the study of HE for over 60 years. This review aims at summarizing and clarifying the role of neurophysiologic techniques in the study of HE.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-08-03
      DOI: 10.1016/j.jceh.2014.06.007
  • Diagnosis of Minimal Hepatic Encephalopathy
    • Authors: Karin Weissenborn
      Abstract: Minimal hepatic encephalopathy (mHE) has significant impact upon a liver patient's daily living and health related quality of life. Therefore a majority of clinicians agree that mHE should be diagnosed and treated. The optimal means for diagnosing mHE, however, is controversial. This paper describes the currently most frequently used methods—EEG, critical flicker frequency, Continuous Reaction time Test, Inhibitory Control Test, computerized test batteries such as the Cognitive Drug Research test battery, the psychometric hepatic encephalopathy score (PHES) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)—and their pros and cons.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-07-31
      DOI: 10.1016/j.jceh.2014.06.005
  • Infections After Orthotopic Liver Transplantation
    • Authors: Mark Pedersen; Anil Seetharam
      Abstract: Opportunistic infections are a leading cause of morbidity and mortality after orthotopic liver transplantation. Systemic immunosuppression renders the liver recipient susceptible to de novo infection with bacteria, viruses and fungi post-transplantation as well to reactivation of pre-existing, latent disease. Pathogens are also transmissible via the donor organ. The time from transplantation and degree of immunosuppression may guide the differential diagnosis of potential infectious agents. However, typical systemic signs and symptoms of infection are often absent or blunted after transplant and a high index of suspicion is needed.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-07-24
      DOI: 10.1016/j.jceh.2014.07.004
  • Pathogenesis of Hepatic Encephalopathy: Role of Ammonia and Systemic
    • Authors: Dominic R. Aldridge; Edward J. Tranah, Debbie L. Shawcross
      Abstract: The syndrome we refer to as Hepatic Encephalopathy (HE) was first characterized by a team of Nobel Prize winning physiologists led by Pavlov and Nencki at the Imperial Institute of Experimental Medicine in Russia in the 1890's. This focused upon the key observation that performing a portocaval shunt, which bypassed nitrogen-rich blood away from the liver, induced elevated blood and brain ammonia concentrations in association with profound neurobehavioral changes. There exists however a spectrum of metabolic encephalopathies attributable to a variety (or even absence) of liver hepatocellular dysfunctions and it is this spectrum rather than a single disease entity that has come to be defined as HE.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-06-30
      DOI: 10.1016/j.jceh.2014.06.004
  • Hepatic Encephalopathy and Sleepiness: An Interesting Connection'
    • Authors: Sara Montagnese; Matteo Turco, Piero Amodio
      Abstract: Sleep-wake abnormalities in patients with cirrhosis have been traditionally associated with hepatic encephalopathy (HE). In recent years, a certain amount of work has been devoted to the study of this relationship. This has lead to a modified picture, with weakening of the association between HE and poor night sleep, and the emergence of stronger links between HE and excessive daytime sleepiness. This brief review focuses on the evidence in favor of the interpretation of HE as a sleepiness syndrome, and on the diagnostic, therapeutic and social implications of such an interpretation.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-06-29
      DOI: 10.1016/j.jceh.2014.06.006
  • A Tribute to a Dear Colleague
    • Authors: Roger F. Butterworth
      Abstract: It was with great sadness that we learned that Joan (Juan) Cordoba, a dear colleague and friend had passed away. Born in Barcelona, Juan was quintessentially Spanish and a proud Catalan. He was the eldest of five children. Armed with his MD degree (cum laude in all subjects) from The University of Barcelona in 1987, Juan trained with the best on both sides of the Atlantic but it was the time he spent with Dr Andy Blei at North Western University in Chicago that fostered what was to become a career-long interest in hepatic encephalopathy (HE).
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-06-20
      DOI: 10.1016/j.jceh.2014.05.001
  • Approach to Clinical Syndrome of Jaundice and Encephalopathy in Tropics
    • Authors: Anil C. Anand; Hitendra K. Garg
      Abstract: A large number of patients present with jaundice and encephalopathy in tropical country like India and acute liver failure is the usual cause. Clinical presentation like ALF is also a complication of many tropical infections, and these conditions may mimic ALF but may have subtle differences from ALF. Moreover, what hepatologists see as acute liver failure in tropics is different from what is commonly described in Western Textbooks. Paracetamol overdose, which is possibly the commonest cause of ALF in UK and USA, is hardly ever seen in India.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-06-07
      DOI: 10.1016/j.jceh.2014.05.007
  • Management of Overt Hepatic Encephalopathy
    • Authors: Praveen Sharma; Barjesh C. Sharma
      Abstract: Hepatic encephalopathy (HE) is an important complication of cirrhosis with significant morbidity and mortality. Management of HE primarily involves avoidance of precipitating factors and administration of various ammonia-lowering therapies such as non-absorbable disaccharides, antimicrobial agents like rifaximin and l-ornithine l-aspartate. The non-absorbable disaccharides which include lactulose and lactitol are considered the first-line therapy for the treatment of HE and in primary and secondary prophylaxis of HE.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-05-08
      DOI: 10.1016/j.jceh.2014.04.004
  • Decellularization and Cell Seeding of Whole Liver Biologic Scaffolds
           Composed of Extracellular Matrix
    • Authors: Denver M. Faulk; Justin D. Wildemann, Stephen F. Badylak
      Abstract: The definitive treatment for patients with end-stage liver disease is orthotropic transplantation. However, this option is limited by the disparity between the number of patients needing transplantation and the number of available livers. This issue is becoming more severe as the population ages and as the number of new cases of end-stage liver failure increases. Patients fortunate enough to receive a transplant are required to receive immunosuppressive therapy and must live with the associated morbidity.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-03-31
      DOI: 10.1016/j.jceh.2014.03.043
  • Management of Covert Hepatic Encephalopathy
    • Authors: Abhijeet Waghray; Nisheet Waghray, Kevin Mullen
      Abstract: Hepatic encephalopathy is a reversible progressive neuropsychiatric disorder that encompasses a wide clinical spectrum. Covert hepatic encephalopathy is defined as patients with minimal hepatic encephalopathy and Grade I encephalopathy by West-Haven Criteria. Terminology such as “sub-clinical”, “latent”, and “minimal” appear to trivialize the disease and have been replaced by the term covert. The lack of clinical signs means that covert hepatic encephalopathy is rarely recognized or treated outside of clinical trials with options for therapy based on patients with episodic hepatic encephalopathy.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-02-27
      DOI: 10.1016/j.jceh.2014.02.007
  • Pathogenesis of Hepatic Encephalopathy and Brain Edema in Acute Liver
    • Authors: Roger F. Butterworth
      Abstract: Neuropathologic investigations in acute liver failure (ALF) reveal significant alterations to neuroglia consisting of swelling of astrocytes leading to cytotoxic brain edema and intracranial hypertension as well as activation of microglia indicative of a central neuroinflammatory response. Increased arterial ammonia concentrations in patients with ALF are predictors of patients at risk for the development of brain herniation. Molecular and spectroscopic techniques in ALF reveal alterations in expression of an array of genes coding for neuroglial proteins involved in cell volume regulation and mitochondrial function as well as in the transport of neurotransmitter amino acids and in the synthesis of pro-inflammatory cytokines.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-02-14
      DOI: 10.1016/j.jceh.2014.02.004
  • Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid
           on Thioacetamide-induced Rat Liver Fibrosis
    • Authors: Vyacheslav U. Buko; Oxana Y. Lukivskaya, Elena E. Naruta, Elena B. Belonovskaya, Horst-Dietmar Tauschel
      Abstract: Effects of norursodeoxycholic acid (norUDCA) and ursodeoxycholic acid (UDCA) on liver fibrosis progression and liver fibrosis reversal in thioacetamide (TAA)-treated rats were studied.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-02-10
      DOI: 10.1016/j.jceh.2014.02.001
  • Portal Vein Thrombosis in Cirrhosis
    • Authors: Kaiser Raja; Mathew Jacob, Sonal Asthana
      Abstract: Portal vein thrombosis (PVT) is being increasingly recognized in patients with advanced cirrhosis and in those undergoing liver transplantation. Reduced flow in the portal vein is probably responsible for clotting in the spleno-porto-mesenteric venous system. There is also increasing evidence that hypercoagulability occurs in advanced liver disease and contributes to the risk of PVT. Ultrasound based studies have reported a prevalence of PVT in 10–25% of cirrhotic patients without hepatocellular carcinoma.
      Citation: Journal of Clinical and Experimental Hepatology (2013)
      PubDate: 2013-12-09
      DOI: 10.1016/j.jceh.2013.12.003
  • Magnetic Resonance Imaging and Spectroscopy in Hepatic Encephalopathy
    • Authors: Laia Chavarria; Juan Cordoba
      Abstract: Hepatic encephalopathy is a brain alteration associated to liver failure that produces cognitive impairments at long term. Neuroimaging are non-invasive methods for the study of the brain by means of spectroscopy and imaging techniques. These technologies give huge information about cerebral metabolism and water distribution to explore brain pathways involved in the pathogenesis of hepatic encephalopathy. Furthermore, new magnetic resonance implementations such as voxel-based morphometry or resting-state functional magnetic resonance imaging allow studying brain atrophy and neuronal connectivity of the cerebral network involved in the neurocognitive impairments observed in the patients.
      Citation: Journal of Clinical and Experimental Hepatology (2013)
      PubDate: 2013-10-28
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014